{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:47:37Z","timestamp":1764510457910,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.clml.2013.03.021","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T16:15:47Z","timestamp":1370880947000},"page":"579-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage Therapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Marylou","family":"Cardenas-Turanzas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi-Kashani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherry A.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.03.021_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.clinthera.2011.04.004","article-title":"A\u00a0network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly","volume":"33","author":"Ziogas","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2013.03.021_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.021_bib3","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1182\/blood-2010-07-296392","article-title":"Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.03.021_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MOH.0b013e32834ff4e1","article-title":"Treatment for relapsed acute myeloid leukemia: what is new?","volume":"19","author":"Ofran","year":"2012","journal-title":"Curr Opin Hematol"},{"year":"2005","series-title":"Reviewer guidance: conducting a clinical safety review of a new product application and preparing a report on the review. Good review practices","author":"US Department of Health and Human Services","key":"10.1016\/j.clml.2013.03.021_bib5"},{"year":"2009","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","author":"US Department of Health and Human Services","key":"10.1016\/j.clml.2013.03.021_bib6"},{"key":"10.1016\/j.clml.2013.03.021_bib7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2013.03.021_bib8","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ejca.2008.04.017","article-title":"90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?","volume":"44","author":"Arkenau","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2013.03.021_bib9","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2010-05-285387","article-title":"Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm","volume":"116","author":"Walter","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013001237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:46Z","timestamp":1761870286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S2152265013001237"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.021","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expectations of Serious Adverse Events at the End of Life of Patients With Acute Myeloid Leukemia Who Receive Salvage Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}